reports
- Robert Sassoon
Excited About 2024 After a Breakout 2023
Water Tower Research hosted CEO and Co-Founder Ben Lightburn in a fireside chat on April 4, 2024. Lightburn discussed the latest developments in Filament’s drug development programs, expansion into new markets, financial strategy, and milestone targets in 2024. This report contains a transcript of the conversation, which can be accessed on demand. Link is accessible in our full report. 2023 achievements highlighted; progress continues in 2024. More important than quintupling its reported revenue...
- Robert Sassoon
Buttressed by a Robust IP Moat
Water Tower Research hosted CEO and Co-Founder Ben Lightburn on November 14, 2023, for a fireside chat. Lightburn discussed Filament’s unique approach to psychedelic drug development, provided an overview of and progress update on the company’s drug development programs, explained the value of its large and expanding partnership network, and why the company is merging with SPAC Jupiter Acquisition Corp. (NASDAQ: JAQC). This report contains a transcript of the conversation, which can be accessed ...
- Robert Sassoon
Pioneer in Botanical Psychedelics Drug Development
Leader in naturally derived psychedelics. Stewarded by a leadership team steeped in the expertise of botanical extraction, Filament Health Corp. listed on the CBOE:FH (formally NEO) and OTCQB:FLHLF, can count itself as the first and only company that has naturally derived psychedelics in clinical trials. A multibillion-dollar white space psychedelics opportunity beckons. Despite the long history and use of botanical psychedelics and documented evidence of their safety and efficacy, the psychede...
- Robert Sassoon
Water Tower Podcast Recap: A Conversation with CEO Ben Lightburn
CEO and Co-Founder of Filament Health Ben Lightburn joined The Water Tower Hour podcast. The company is the first and currently the only exclusively natural psychedelic-derived drug developer, with the initial focus on ‘magic mushroom’ compounds, led by psilocybin and psilocin. Lightburn explains what brought him to the psychedelics space and the reasons behind the launch of Filament in 2020. Lightburn highlights what he believes sets Filament’s naturally-derived drug candidates apart from syn...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.